Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

HUO Liman; DUAN Yangyang; LIANG Ping; SHAN Bin; SUN Xiaoli; FENG Rui

doi:10.6039/j.issn.1001-0408.2025.17.10

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

更新时间：2025-09-29

- Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 17, Pages: 2141-2147(2025)
- 作者机构：
  
  1.河北医科大学第四医院药学部，石家庄　050011
  2.河北医科大学药学院，石家庄　050017
  3.天津大学卫生应急学院，天津　300072
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.17.10
  CLC： R956;R979.1
- Received：12 May 2025，
  
  Revised：2025-08-15，
  
  Accepted：18 August 2025，
  
  Published：15 September 2025
- 稿件说明：
移动端阅览
霍丽曼,段杨洋,梁平,等.度伐利尤单抗联合化疗方案一线治疗晚期胆道癌的药物经济学评价[J].中国药房,2025,36(17):2141-2147.

HUO Liman,DUAN Yangyang,LIANG Ping,et al.Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer[J].ZHONGGUO YAOFANG,2025,36(17):2141-2147.
霍丽曼,段杨洋,梁平,等.度伐利尤单抗联合化疗方案一线治疗晚期胆道癌的药物经济学评价[J].中国药房,2025,36(17):2141-2147. DOI： 10.6039/j.issn.1001-0408.2025.17.10.

HUO Liman,DUAN Yangyang,LIANG Ping,et al.Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer[J].ZHONGGUO YAOFANG,2025,36(17):2141-2147. DOI： 10.6039/j.issn.1001-0408.2025.17.10.

摘要

目的

从中国卫生体系角度评估度伐利尤单抗联合化疗方案用于晚期胆道癌一线治疗的经济性。

方法

基于TOPAZ-1临床试验数据，构建包含无进展生存、疾病进展（PD）及死亡三状态的马尔可夫模型，模拟周期为21 d，研究时限为10年。观察组患者采用度伐利尤单抗联合吉西他滨+顺铂化疗方案，对照组患者使用安慰剂联合相同化疗方案。评估指标为质量调整生命年（QALY）与增量成本-效果比（ICER），设定意愿支付（WTP）阈值为3倍2024年中国人均国内生产总值（GDP）（287 247元/QALY），并开展敏感性分析与情境分析。

结果

基础分析结果显示，观察组相对于对照组方案的ICER为1 166 344.46元/QALY，显著高于WTP阈值，不具备经济性。单因素敏感性分析结果表明，PD状态效用值、贴现率、度伐利尤单抗成本及无进展生存状态效用值为影响ICER的主要因素。概率敏感性分析结果显示，在上述WTP阈值下，该方案的可接受概率为0，进一步验证了基础分析结果的稳健性。情境分析中，考虑患者援助计划后，ICER下降至235 885.16元/QALY，低于上述WTP阈值，表明该方案在援助机制支持下具备经济性。然而，在以3倍2024年甘肃省（2024年全国GDP最低省份）人均GDP（158 475元/QALY）设定的区域WTP阈值下，ICER仍高于WTP阈值，不具备区域经济性。

结论

在当前价格水平下，度伐利尤单抗联合化疗方案用于晚期胆道癌一线治疗在中国不具备经济性；虽然引入患者援助计划可显著降低ICER，使其在以3倍2024年中国人均GDP作为的WTP阈值下具备经济性，然而在低收入地区，受限于较低的支付能力，该方案仍不具备经济性。

Abstract

OBJECTIVE

To assess the cost-effectiveness of durvalumab combined with chemotherapy as a first-line treatment for advanced biliary tract cancer from the perspective of the Chinese healthcare system.

METHODS

Using data from the TOPAZ-1 clinical trial， a three-state Markov model comprising progression-free survival （PFS）， progressive disease （PD） and death was developed， with a cycle length of 21 days and a 10-year time horizon. Patients in the observation group received durvalumab in combination with gemcitabine and cisplatin， whereas those in the control group received placebo plus the same chemotherapy regimen. The evaluation indexes were quality-adjusted life year （QALY） and the incremental cost-effectiveness ratio （ICER）. The willingness-to-pay （WTP） threshold was set at three times the 2024 Chinese per capita gross domestic product （GDP）（287 247 yuan/QALY）. The sensitivity analyses， along with scenario analyses， were performed.

RESULTS

In the base-case analysis， the ICER of observation group compared to control group was 1 166 344.46 yuan/QALY， far exceeding the WTP threshold， indicating that the regimen was not cost-effective. One-way sensitivity analysis identified the PD state utility， discount rate， cost of durvalumab， and PFS state utility as the main drivers of ICER variation. Probabilistic sensitivity analysis showed that， at the above WTP threshold， the probability of the acceeptance of this regimen was 0， further supporting the robustness of the base-case findings. In the scenario analysis， inclusion of a patient assistance program reduced the ICER to 235 885.16 yuan/QALY， below the above WTP threshold， suggesting cost-effectiveness under this assistance program. However， when applying a regional WTP threshold set at three times the per capita GDP （158 475 yuan/QALY） of Gansu Province （the province with the lowest GDP in China in 2024）， the ICER remained above the threshold， indicating that the regimen was not cost-effective at the regional level.

CONCLUSIONS

At current pricing， durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer is not cost-effective in China. Although the introduction of a patient assistance program can substantially reduce the ICER and achieve cost-effectiveness at a WTP threshold set at three times the 2024 per capita GDP of China， due to limited affordability in low-income areas， the program remains not cost-effective.

关键词

Keywords

references

刘磊，王乔乔，张梅，等 . 晚期胆道癌靶向治疗新进展 [J ] . 肝胆外科杂志， 2025 ， 33 （ 1 ）： 75 - 80 .

BANALES J M ， MARIN J J G ， LAMARCA A ， et al . Cholangiocarcinoma 2020：the next horizon in mechanisms and management [J ] . Nat Rev Gastroenterol Hepatol ， 2020 ， 17 （ 9 ）： 557 - 588 .

王佳，李恩孝，樊扬威 . 胆道癌围手术期治疗进展 [J ] . 现代肿瘤医学， 2022 ， 30 （ 22 ）： 4208 - 4213 .

VALLE J ， WASAN H ， PALMER D H ， et al . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer [J ] . N Engl J Med ， 2010 ， 362 （ 14 ）： 1273 - 1281 .

MERTERS J ， LAMARCA A . Integrating cytotoxic，targeted and immune therapies for cholangiocarcinoma [J ] . J Hepatol ， 2023 ， 78 （ 3 ）： 652 - 657 .

OH D Y ， HE A R ， QIN S K ， et al . Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer [J ] . NEJM Evid ， 2022 ， 1 （ 8 ）： EVIDoa2200015 .

OH D Y ， HE A R ， BOUATTOUR M ， et al . Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer （TOPAZ-1）：updated overall survival from a randomised phase 3 study [J ] . Lancet Gastroenterol Hepatol ， 2024 ， 9 （ 8 ）： 694 - 704 .

VOGEL A ， CHEN L T ， HE A R ， et al . Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab （D） plus gemcitabine and cisplatin （GC） in advanced biliary tract cancer （BTC） [J ] . J Clin Oncol ， 2022 ， 40 （ Suppl.16 ）： 4075 .

YE Z M ， XU Z ， LI H ， et al . Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer [J ] . Front Public Health ， 2023 ， 11 ： 1046424 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）胆道恶性肿瘤诊疗指南2023 [M ] . 北京：人民卫生出版社， 2023 ： 66 - 68 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 3 - 5 .

国家统计局 . 中华人民共和国2024年国民经济和社会发展统计公报 [EB/OL ] .（ 2025-02-28 ）[ 2025-04-15 ] . https：// www.stats.gov.cn/sj/zxfb/202502/t20250228_1958817.html https://www.stats.gov.cn/sj/zxfb/202502/t20250228_1958817.html .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

DJALALOV S ， BECA J ， EWARA E M ， et al . A comparison of different analysis methods for reconstructed survival data to inform cost-effectiveness analysis [J ] . Pharmacoeconomics ， 2019 ， 37 （ 12 ）： 1525 - 1536 .

王凯旋，李顺平，窦蕾，等 . 帕博利珠单抗一线治疗不可切除或转移性MSI-H/dMMR结直肠癌的成本效果分析 [J ] . 中国新药与临床杂志， 2024 ， 43 （ 3 ）： 229 - 235 .

YANG F ， FU Y ， KUMAR A ， et al . Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China [J ] . Ann Transl Med ， 2021 ， 9 （ 15 ）： 1226 .

WU B ， DONG B J ， XU Y J ， et al . Economic evaluation of first-line treatments for metastatic renal cell carcinoma：a cost-effectiveness analysis in a health resource-limited setting [J ] . PLoS One ， 2012 ， 7 （ 3 ）： e32530 .

齐冉，聂旭阳，刘旭婷，等 . 斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2023 ， 34 （ 11 ）： 1368 - 1373 .

NAFEES B ， STAFFORD M ， GAVRIEL S ， et al . Health state utilities for non-small cell lung cancer [J ] . Health Qual Life Outcomes ， 2008 ， 6 ： 84 .

国家卫生健康委员会 . 中国居民营养与慢性病状况报告：2020 年[J ] . 营养学报， 2020 ， 42 （ 6 ）： 521 .

ZHAO Q L ， XIE R X ， ZHONG W F ， et al . Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial [J ] . Cost Eff Resour Alloc ， 2023 ， 21 （ 1 ）： 19 .

KASHIWA M ， MAEDA H . Comparative cost-effectiveness of gemcitabine and cisplatin in combination with S-1，durvalumab，or pembrolizumab as first-line triple treatment for advanced biliary tract cancer [J ] . J Gastrointest Cancer ， 2024 ， 55 （ 4 ）： 1569 - 1580 .

Canadian Agency for Drugs and Technologies in Health . Durvalumab （Imfinzi） for advanced biliary tract cancer：economic evaluation report [EB/OL ] . （ 2023-08-30 ）[ 2025-06-09 ] . https：//www.cadth.ca/durvalumab-imfinzi-advanced- biliary-tract-cancer-economic-evaluation-report https://www.cadth.ca/durvalumab-imfinzi-advanced-biliary-tract-cancer-economic-evaluation-report .

National Institute for Health and Care Excellence . Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer：technology appraisal guidance [EB/OL ] . （ 2023-06-16 ）[ 2025-06-16 ] . https：//www.nice.org.uk/guidance/ta944 https://www.nice.org.uk/guidance/ta944 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer

Pharmacoeconomic evaluation of finerenone combined with standard regimen in the treatment of heart failure with preserved or mildly reduced ejection fraction

Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

Related Author

GAO Chuan

DONG Juanni

LONG Lihui

WEN Enhui

RONG Biaoxue

ZHANG Ranran

LIU Guoqiang

ZHANG Yuxi

Related Institution

Clinical Pharmaceutics Room， the First Affiliated Hospital of Xi’an Medical University

Dept. of Oncology， the First Affiliated Hospital of Xi’an Medical University

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Dept. of Pharmacy， People’s Hospital of Bozhou

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰